# OnCo record alkove-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/alkove-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "alkove-1", "NCT05384626" ;
  schema:name "ALKOVE-1"@en ;
  schema:description "The registrational study of a fourth-generation ALK pill designed to work after lorlatinib and to spare the brain-related side effects."@en ;
  schema:url <https://onco.cc/trials/alkove-1/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05384626>, <https://investors.nuvalent.com/2026-04-07-Nuvalent-Announces-Submission-of-New-Drug-Application-to-FDA-for-Neladalkib-in-TKI-Pre-treated-Advanced-ALK-positive-NSCLC> ;
  onco:status "positive" ;
  onco:phase "1/2" ;
  schema:startDate "2022-06-09" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:drugs <https://onco.cc/drugs/neladalkib/> ;
  onco:companies <https://onco.cc/companies/nuvalent/> .